Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction.

Abstract

INTRODUCTION:

Vardenafil is a potent and selective phosphodiesterase 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction (ED). Fixed-dose and flexible-dose studies have previously established the efficacy and tolerability of vardenafil.

AIM:

To assess, besides the usual measures of efficacy, the quality of erection, satisfaction with the sexual experience, symptoms of depression, and overall confidence.

METHODS:

This 12-week double-blind, placebo-controlled flexible-dose study assessed patients from the general ED population. Patients underwent a 4-week treatment-free period before randomization to vardenafil or matching placebo. Initial dosage was vardenafil 10 mg for 4 weeks. At 4 weeks, patients could switch to 5 or 20 mg (or corresponding placebo), or remain on 10 mg for an additional 4 weeks; dose switching was also optional for the last 4 weeks. This paper describes per-patient success in satisfaction with hardness of erection, satisfaction with overall sexual experience, effect on overall self-confidence, and an assessment of symptoms of depression using the Center for Epidemiologic Studies Depression Scale.

RESULTS:

Mean per-patient satisfaction rates with erection hardness increased after vardenafil treatment to 43%, 59%, and 63% at weeks 4, 8, and 12, respectively, compared to placebo with 10%, 21%, and 23% (all P < 0.005 vs. placebo). Vardenafil also improved mean per-patient overall satisfaction 50-65% over the 4-12 week study period compared with 17-28% for placebo (P < 0.005). Symptoms of depression were statistically significantly reduced compared to placebo (P = 0.02); the effect was observed particularly in patients who were depressed at baseline (P = 0.01). Significantly more patients in the vardenafil treatment group reported improved self-confidence than those who received placebo (P < 0.005).

CONCLUSIONS:

A flexible-dose regimen of vardenafil improved satisfaction rates, symptoms of depression, and self-confidence, providing patients with an effective ED therapy that contributes to overall improvements in sexual function and confidence.

• Authors: Dimitrios Hatzichristou, Beatrice Cuzin, Antonio Martin-Morales, Jacques Buvat, Hartmut Porst, Nicole Laferriere, Tiemol Jerg Bandel, Francesco Montorsi, Vardenafil Study Group
• Journal: The journal of sexual medicine (J Sex Med) Vol. 2 Issue 1 Pg. 109-16 (Jan 2005) ISSN: 1743-6095 [Print] Netherlands
• PMID: 16422913 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Imidazoles
• Phosphodiesterase Inhibitors
• Piperazines
• Sulfones
• Triazines
• Vardenafil Dihydrochloride

Topics

• Analysis of Variance
• Depression (prevention & control)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Erectile Dysfunction (drug therapy)
• Humans
• Imidazoles (pharmacology, therapeutic use)
• Logistic Models
• Male
• Middle Aged
• Patient Satisfaction
• Phosphodiesterase Inhibitors (pharmacology, therapeutic use)
• Piperazines (pharmacology, therapeutic use)
• Prospective Studies
• Self Concept
• Sulfones (pharmacology, therapeutic use)
• Triazines (pharmacology, therapeutic use)
• Vardenafil Dihydrochloride